Why AndroGel (testosterone topical) Causes Transfer to Women and Children: The Mechanism Explained

AndroGel is a brand-name hydroalcoholic gel formulation of testosterone, an androgen hormone, FDA-approved for testosterone replacement in men with confirmed hypogonadism. It is applied daily to the skin of the shoulders, upper arms, or abdomen. It is not the same product as testosterone injections, subcutaneous pellets, intranasal testosterone (Natesto), or scrotal testosterone patches, all of which have different transfer risk profiles discussed below.

The direct answer: AndroGel leaves an active testosterone residue in the outer skin layer for several hours after application. When another person's skin, most often a partner's or a child's, makes direct contact with that residue, testosterone can absorb through their skin and raise their hormone levels enough to cause physical changes (virilization). This is a recognized, FDA-labeled risk, not a theoretical one; it carries a Boxed Warning, and case reports of pediatric virilization from secondary household exposure have been published. Handwashing, covering the application site with clothing, and avoiding skin contact until the site is washed are the evidence-based prevention steps; a formulation switch to a non-topical testosterone product removes the transfer route entirely.

What is established, what is plausible, and what is not established

Established: Topical testosterone gel deposits an androgen residue on the skin that can transfer to another person through direct skin contact, and this transfer has caused documented virilization in women and children, including a published case report and review of both published and unpublished transfer cases. This risk is significant enough that the FDA required a Boxed Warning on testosterone gel products.

Plausible but not rigorously quantified in the material available here: Specific numbers sometimes circulated online, such as an exact percentage reduction in transfer from wearing a shirt, or an exact multiple of baseline serum testosterone from a defined contact duration, come from pharmacokinetic sub-studies that were part of the drug's development and post-marketing surveillance program. We were not able to verify the original study behind each specific number for this draft, so those precise figures are omitted here rather than repeated without a checked source. The general direction, clothing barriers and handwashing meaningfully reduce transfer, is well supported; the exact magnitude should be confirmed against the primary literature before being quoted as fact.

Not established: There is no reliable published incidence rate for how common secondary transfer virilization is among households using AndroGel, and there is no validated "safe" contact-free waiting time that applies to every patient, dose, or skin site. Body size, dose, application site, and how thoroughly the site is washed all change the actual risk in ways that have not been reduced to a single number.

How testosterone gets from the tube to someone else's skin

AndroGel's alcohol carrier evaporates within minutes of application, leaving testosterone embedded in the outer layer of skin (the stratum corneum). This is a hormone depot, not a static stain, and it continues to release testosterone both into the user's own circulation and outward onto the skin surface for a period of hours. Testosterone is a lipophilic (fat-soluble) steroid, which is part of why it moves readily from one person's stratum corneum into another's on direct contact, following the same kind of concentration-driven diffusion that governs absorption of the drug into the user's own bloodstream.

The FDA label for AndroGel describes this transfer risk explicitly and instructs patients to wash the application site with soap and water before anticipated skin-to-skin contact, and to wash hands immediately after applying the gel. The label's Boxed Warning exists specifically because this transfer has caused real-world virilization, not because of a theoretical pharmacology concern.

Why children are especially vulnerable

A child's small body size means a transfer event that would be barely detectable in an adult woman can represent a pharmacologically active dose relative to a young child's baseline hormone exposure. Before puberty, the hypothalamic-pituitary-gonadal axis is largely quiescent, but androgen receptors in genital tissue, skin, and the brain remain fully functional. Exogenous testosterone can bind those receptors directly, and reported effects in children exposed this way include premature pubic hair, clitoral or penile enlargement, accelerated bone maturation, and behavioral changes such as increased aggression.

A published case report and literature review of hyperandrogenism following secondary exposure to topical testosterone gel documents this pattern in real patients and summarizes both published and unpublished cases identified at the time (Yu et al., 2009). Readers and prescribers evaluating a possible exposure in a specific child should treat this as documented clinical evidence that the exposure route and the resulting physical changes are real, while recognizing that the exact number of cases in circulation, and how representative they are of overall risk, requires review of the primary literature rather than a single summary figure.

Which application sites and behaviors carry the most transfer risk

AndroGel is labeled for the shoulders, upper arms, and abdomen, all sites likely to contact other people during ordinary household life: hugging, carrying a child, or sitting close together. Hands are a separate transfer route. Even when the application site itself is covered, testosterone residue left on the palms and fingers during application can transfer to a child who is fed, held, or diapered afterward. This is why the label instructs immediate handwashing with soap and water after every application, separate from any instruction about the application site itself.

Genital and scrotal testosterone formulations exist for other indications and are not the subject of this article; they carry their own separate transfer considerations for sexual partners that a prescriber should address directly with the patient.

What actually reduces transfer risk

Because transfer depends on direct contact with the residual testosterone film, anything that physically separates that film from another person's skin interrupts the route.

• Wash hands with soap and water immediately after application. Alcohol-based hand sanitizer is not a validated substitute; it may redistribute gel rather than remove it.
• Cover the application site with clothing once the gel has dried. A physical barrier is the most direct way to prevent skin-to-skin contact regardless of how much time has passed.
• Wash the application site with soap and water before anticipated close contact (for example, before intimate contact or before holding an infant for an extended period). This is more reliable than simply waiting, since residue has been reported to remain present for hours.
• Time alone is not a guarantee. Waiting reduces surface residue but the labeled instructions do not establish a fixed "safe" number of hours after which contact becomes risk-free; washing the site is the more dependable step when close contact is planned.
• Consider a non-topical formulation (injectable testosterone cypionate or enanthate, or a subcutaneous pellet) if reliable prevention is not realistic in the household, particularly where there are infants, toddlers, or a pregnant partner. This is a formulation decision for the prescriber and patient, not a self-directed switch.

Signs of possible secondary exposure

In prepubertal children: pubic or axillary hair appearing earlier than expected, clitoral enlargement in girls, penile or testicular changes in boys, new acne, or unexplained increases in aggression. The FDA's drug safety communication on testosterone products describes pediatric virilization cases identified through household exposure to topical testosterone, in some cases not recognized as drug-related until an endocrine workup was performed.

In adult women: new or worsening acne, increased facial or body hair, clitoral enlargement, voice deepening, or menstrual irregularity.

In pregnant women: testosterone crosses the placenta, and exposure during the window of fetal genital differentiation is a recognized concern for virilization of a female fetus. Pregnant women should avoid contact with AndroGel application sites, and any pregnancy in a household using topical testosterone should be reported to the prescriber promptly so the formulation can be reviewed.

Any of these signs, especially in a child, warrants prompt evaluation by a pediatrician or pediatric endocrinologist rather than watchful waiting at home. Initial workup typically includes a serum testosterone level and, in children, a bone age assessment; this article does not provide individualized diagnostic or dosing guidance, and evaluation should happen through a clinician who knows the child's history.

A decision framework: should this household switch away from topical testosterone?

Use this to structure the conversation with the prescriber rather than to self-diagnose or self-switch.

The common thread: precautions are effective when followed exactly, but any household where consistent hand hygiene and site covering cannot be guaranteed is a reasonable candidate for switching to a delivery method that does not leave hormone on the skin surface, such as injectable testosterone or a subcutaneous pellet. That decision belongs to the prescriber and patient together, weighing the patient's own reasons for choosing a topical formulation against the transfer risk to others in the home.

---

Frequently asked questions

›How long after my husband applies AndroGel can I safely touch his skin?

The most reliable approach is to wait until he has washed the application site with soap and water, regardless of how much time has passed. The label does not establish a fixed number of hours after which contact becomes risk-free; covering the site with clothing is the more dependable interim barrier if washing isn't practical yet.

›Can I get AndroGel residue just from touching a doorknob or surface he touched?

The documented risk in the labeling and safety literature is direct skin-to-skin contact, either with the treated site or with unwashed hands. Transfer from inanimate surfaces is not the exposure route described in the available evidence.

›My toddler sat on my lap right after I applied AndroGel. What should I do?

Wash the areas of your child's skin that contacted your treated site with mild soap and water, note the date and how long the contact lasted, and watch for any signs of virilization over the following weeks. Tell your child's pediatrician about the exposure, and let your own prescriber know so they can review your application protocol.

›My daughter has pubic hair and she is only 5. Could AndroGel be responsible?

This is a documented pattern. Premature pubic hair in a young child in a household using topical testosterone is a reason for prompt evaluation, not a wait-and-see approach. A pediatrician or pediatric endocrinologist can order a serum testosterone level and a bone age X-ray to start the workup.

›Does washing the application site before expected contact actually help?

Yes. Thoroughly washing the site with soap and water removes surface-level residue and is the step explicitly recommended in the prescribing information before anticipated skin contact. It is a more dependable strategy than simply letting time pass.

›Can AndroGel transfer affect a pregnancy?

Yes, this is a recognized concern. Testosterone crosses the placenta, and androgen exposure during the window of fetal genital differentiation can affect a female fetus. Pregnant women should avoid contact with AndroGel application sites, and the prescriber should be told about any pregnancy in the household so the treatment plan can be reviewed.

›Would switching to testosterone injections eliminate transfer risk for my family?

Injectable testosterone, subcutaneous pellets, and intranasal testosterone do not leave hormone on the skin surface the way a topical gel does, so they do not carry the same secondary contact transfer risk. If reliable prevention isn't realistic in your household, this is worth discussing with your prescriber.

›What testosterone level in a female partner or child would suggest exposure?

Normal ranges vary by lab, age, and sex, and interpreting a single result requires a clinician who can compare it against the right reference range and the person's history. Any unexplained testosterone elevation in a woman or child in a household using topical testosterone is a reasonable prompt for medical evaluation rather than self-interpretation of a lab number.

References

• FDA prescribing information for AndroGel (testosterone gel) describes the transfer risk and required precautions, per the product labeling.
• An FDA drug safety communication has addressed serious risks associated with testosterone product use.
• Yu YM, et al. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. (2009). https://pubmed.ncbi.nlm.nih.gov/18948313/

Specific figures for absorption reduction from clothing coverage and serum testosterone increases after timed skin contact have been reported in the literature, but these values vary between sources and have not been independently confirmed here, so they are not restated.